Replies to post #49 on Biotech Values

[oc1_2]

Hi drbio45,
genr has had Sq for a long time, and your comments are the first I’ve seen claiming the company has had some success in developing new delivery systems. Have I missed some DD (fun intended DewD), or is word getting around from conferences, meetings, and such?

Has anyone been talking to RidgeRunner? His thoughts on the CF results would be appreciated.

Regards,

[mskatiescarletohara]

Dr. Bio....

I think genr is at the point where they can do their 125 to 150 million up front deal with a big pharma.

Well, that would be great, and I think at this juncture it's time for pharma to step in if the FDA Gods are willing to get Squalamine on the market in an expeditious manner. I would like to see a 50/50 split of revenue globally if possible, backed with significant milestone payments payable upon the usual stepping stones...Phase III, NDA submission, marketing approval.

If Levitt isn't ready to deal yet, and pharma isn't wanting to pay then I am okay with him doing a secondary and launching a Phase II with intent to get the Phase III negotiations underway. I am bullish on Squalamine, and I want to see it developed properly, mistakes will only devalue my investment.

This Wednesday he is speaking in Boston, I am hoping he will give some sort of indication of where the company stands with the FDA regarding Squalamine. I am very curious if you, or anyone else here will be at the conference, and lemme know if it's "standing room" only!

Wasn't aware that Squalamine had nasal and transdermal potential, now that is interesting to say the least.

Definitely on the same page as you regarding Phase II.

katie....